- Home
- BANX vs MCRB Comparison
BANX vs MCRB Comparison
Compare BANX & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BANX | MCRB |
|---|---|---|
| Founded | 2013 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 149.8M | 162.7M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | BANX | MCRB |
|---|---|---|
| Price | $21.68 | $14.82 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $14.33 |
| AVG Volume (30 Days) | 23.4K | ★ 84.6K |
| Earning Date | 06-17-2025 | 11-05-2025 |
| Dividend Yield | ★ 9.66% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.35 | 0.62 |
| Revenue | ★ $29,467,794.00 | $351,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ $8.88 | $23.66 |
| Revenue Growth | ★ 2.73 | N/A |
| 52 Week Low | $17.99 | $6.53 |
| 52 Week High | $21.67 | $29.98 |
Technical Indicators
Market Signals| Indicator | BANX | MCRB |
|---|---|---|
| Relative Strength Index (RSI) | 45.84 | 40.64 |
| Support Level | $22.06 | $14.03 |
| Resistance Level | $22.50 | $15.41 |
| Average True Range (ATR) | 0.32 | 0.91 |
| MACD | -0.05 | -0.16 |
| Stochastic Oscillator | 25.23 | 18.51 |
Price Performance
Historical ComparisonAbout BANX ArrowMark Financial Corp.
ArrowMark Financial Corp is a non-diversified, closed-end management investment company. Its objective is to provide stockholders with current income, and to a lesser extent capital appreciation. The company's investments in various portfolios such as debt securities, Trust Preferred and Preferred Securities, preferred securities, exchange-traded funds, money market funds and others.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.